Clinical trials: Obese Adults
Weight Loss
The Safety and Efficacy of a Bone Broth Diet on Weight Loss in Obese Adults
The primary objective of this study is to investigate the safety and efficacy of a bone broth diet on weight loss in obese adults.
- Trial name
- NCT05740670
- Testing
- Dr. Kellyann's Bone Broth
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Veyl Ventures LLC
Liver Fibrosis, Cirrhosis
Fibroscan® and Its Dedicated Probes Efficiency in Obese Patients
The main objective of the study is to evaluate the diagnostic performance of the XL probe for estimating degree of liver fibrosis/cirrhosis in obese patients > 28 kg/m² with various liver diseases in patients with chronic liver…
- Trial name
- NCT00926224
- Testing
- FibroScan M and XL probes
- Where
- 5 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Echosens
Obesity
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.
- Trial name
- NCT00449202
- Testing
- oleoyl-estrone (MP 101)
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 100 people
- Sponsor
- Manhattan Pharmaceuticals
Obesity, Overweight
THE ENLIGHTEN STUDY
The primary objective of this study is to demonstrate the safety and efficacy of the Elipse Gastric Balloon System for the treatment of obese adults.
- Trial name
- NCT03261453
- Testing
- Active Elipse Device
- Where
- 12 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allurion Technologies
Healthy
A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects
The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of PF-04620110 as a modified-release formulation.
- Trial name
- NCT01474941
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteer
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral…
- Trial name
- NCT01018823
- Testing
- Ertugliflozin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Fetal Origin of Adult Diseases
Maternal Transcriptomic Regulation of the Preimplantation Embryo
The aim of this study is to understand the epigenetic and transcriptomic mechanisms that regulate the fetal origin of adult diseases (FOAD), either for the presence of metabolic disorders in the future mothers, such as obesity or…
- Trial name
- NCT02813746
- Testing
- Fitness program, Stop smoking, Endometrial fluid collection
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Igenomix
Overweight and/or Obesity
A Study to Learn How Different Amounts of the Study Medicine Called PF-08656795 Are Tolerated and Act in Adults With Overweight or Obesity
This study will look at how different amounts of the study medicine, called PF-08656795, are tolerated and act in adults with overweight or obesity.
- Trial name
- NCT07876518
- Testing
- PF-08656795
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Type 2 Diabetes Mellitus
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05184322
- Testing
- T2026, Oral ecnoglutide tablet
- Where
- Australia
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Obesity, Weight Management
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
- Trial name
- NCT07073417
- Testing
- XW003 injection, semaglutide injection
- Where
- China
- Volunteers
- 163 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Overweight or Obesity
A Study to Evaluate MWN109 Tablets in Healthy Adult Participants
This is a Phase 1, randomized, double-blind, placebo-controlled, single-and-multiple ascending dose study in which the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of orally administered…
- Trial name
- NCT06938269
- Testing
- MWN109 tablet
- Where
- 2 sites in Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Blood Sugar; High, Overweight and Obesity
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight.
- Conditions
- Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity
- Trial name
- NCT06333496
- Testing
- GLP-1 Booster (GB)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alpine Biotech LLC
Obesity
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity.
- Trial name
- NCT04707313
- Testing
- PF-06882961 (Cohorts 1 and 2), PF-06882961 (Cohort 3)
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 628 people
- Sponsor
- Pfizer
Satiety, Appetite
A Study of NatureU Burn on Satiety in Healthy Adults
This single-center, single-blind, non-randomized crossover exploratory study evaluated the short-term effects of NatureU Burn on postprandial satiety in healthy adults.
- Conditions
- Satiety, Appetite, Food Intake, Fat Disorder
- Trial name
- NUBURN (NCT07597382)
- Testing
- Glucose Reference Food, NatureU Burn Plus Glucose
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- OmniSolutions Laboratory Holdings Limited
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers
This study is the First Time in Human Study for GSK2256294 and will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and repeat oral doses of GSK2256294 administered to healthy male…
- Trial name
- NCT01762774
- Testing
- GSK2256294
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight, Obesity
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
- Trial name
- NCT07767175
- Testing
- NNC0721-8060, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Weight Management
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Trial name
- NCT05813795
- Testing
- Ecnoglutide Low Dosage, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Postprandial Glycemic Control, Prediabetic Overweight and Obese Adults
A Two-part Study of Lembas Edge Evaluating Tolerability and Postprandial Glycemic Control
The goal of part 1 of this clinical trial is to investigate the tolerability of Lembas Edge in healthy adults. The objective of Part 2 of this study is to investigate the efficacy of Lembas Edge on postprandial glycemic control…
- Trial name
- NCT07711288
- Testing
- Low dose alpha-galactosidase-derived peptide, Medium dose alpha-galactosidase-derived peptide, High dose alpha-galactosidase-derived peptide
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Lembas